Zevra Therapeutics Announces Arimoclomol Research Featured
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce
Globe Newswire24-02-2023, 19:35
Predicine to Present Four Studies at 2023 ASCO 17-02-2023, 04:09